Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC

Got story updates? Submit your updates here. ›

Guardant Health NASDAQ: GH executives used a Barclays discussion to outline growth drivers across treatment selection, minimal residual disease (MRD) testing, and colorectal cancer (CRC) screening, while addressing investor questions on clinical utility, reimbursement, and commercial execution.

Why it matters

Guardant Health is a leading precision oncology company that develops non-invasive blood-based cancer diagnostics. The company's growth strategy and product pipeline updates provide insights into the evolving cancer diagnostics market and Guardant's competitive positioning.

The details

In treatment selection, Guardant highlighted monitoring for ESR1 mutations in breast cancer as an emerging opportunity, with the potential for 40,000 patients to be candidates for this type of testing. The company also discussed FDA approval for its Guardant360 test in colorectal cancer, which it believes can increase physician confidence and utilization. On the MRD front, Guardant's Reveal product has been its fastest-growing oncology product, and the company is preparing to launch Reveal Ultra, a new tumor-informed MRD test. In screening, Guardant's Shield CRC test had a strong launch, and the company is focused on reaching unscreened patients in primary care settings.

• Guardant received FDA approval for ESR1 testing in breast cancer a couple years ago.
• An FDA decision on the SERENA-6 trial is expected in the first half of 2026.
• Guardant360 received FDA approval for colorectal cancer in January 2026.
• Guardant's CRC screening test, Shield, was launched in its first full year.
• Guardant expects to launch its Reveal Ultra MRD test later in 2026.

What they’re saying

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.